A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

CAR-T for R/R B-NHL

NCT03196830 ·Status: UNKNOWN ·Phase: PHASE2

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

NCT03483688 ·Status: COMPLETED ·Phase: PHASE1

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

NCT03488160 ·Status: UNKNOWN ·Phase: NA

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

NCT04169932 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

NCT06446128 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

NCT06838832 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07234045 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

NCT05436223 ·Status: RECRUITING ·Phase: PHASE2

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

NCT05741359 ·Status: RECRUITING ·Phase: PHASE1

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

NCT03881761 ·Status: UNKNOWN ·Phase: PHASE1

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

NCT04532268 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

NCT04887012 ·Status: UNKNOWN ·Phase: PHASE1

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

NCT04697290 ·Status: SUSPENDED ·Phase: EARLY_PHASE1

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

NCT06850285 ·Status: RECRUITING ·Phase: NA

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

NCT05420493 ·Status: RECRUITING ·Phase: PHASE1

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

NCT06210243 ·Status: TERMINATED ·Phase: PHASE1

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

NCT02842138 ·Status: UNKNOWN ·Phase: PHASE1

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

NCT05659628 ·Status: RECRUITING ·Phase: PHASE1

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07200479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

NCT06464185 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

NCT05105867 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

NCT02728882 ·Status: UNKNOWN ·Phase: NA

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

NCT05651100 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT05673447 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

NCT06834529 ·Status: RECRUITING ·Phase: PHASE1/PHASE2